Exposure-Response (E-R) Analysis of Progression Free Survival (PFS) for Nivolumab in Combination with Ipilimumab in Patients with Previously Untreated Advanced Melanoma

被引：0
|
作者：
Feng, Yan [1 ]
Wang, Xiaoning [1 ]
Statkevich, Paul [1 ]
Roy, Amit [1 ]
机构：
[1] Bristol Myers Squibb, Princeton, NJ USA
来源：
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS | 2015年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
T-56
引用
收藏
页码：S67 / S67
页数：1
相关论文
共 50 条
  • [1] Characterizing Exposure-Response (E-R) Relationship of Safety for Nivolumab in Combination with Ipilimumab in Patients with Previously Untreated Advanced Melanoma
    Wang, Xiaoning
    Feng, Yan
    Statkevich, Paul
    Roy, Amit
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2015, 42 : S37 - S38
  • [2] Ipilimumab Exposure-Response (E-R) Analysis of Overall Survival (OS) in Patients with Advanced Melanoma
    Vezina, Heather E.
    Feng, Yan
    Roy, Amit
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2015, 42 : S28 - S28
  • [3] Exposure-Response Analysis of Nivolumab in Patients With Previously Treated or Untreated Advanced Melanoma
    Bajaj, Gaurav
    Gupta, Manish
    Feng, Yan
    Statkevich, Paul
    Roy, Amit
    JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 57 (12): : 1527 - 1533
  • [4] Characterization of the Pharmacokinetics and Exposure-Response Relationship for Nivolumab in Patients with Previously Treated or Untreated Advanced Melanoma
    Bajaj, Gaurav
    Gupta, Manish
    Feng, Yan
    Statkevich, Paul
    Roy, Amit
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2015, 42 : S36 - S36
  • [5] EXPOSURE-RESPONSE (E-R) ANALYSIS OF OVERALL SURVIVAL (OS) FOR NIVOLUMAB IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER (NSCLC)
    Feng, Y.
    Bajaj, G.
    Agrawal, S.
    Wang, X.
    Bello, A.
    Roy, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S56 - S57
  • [6] Exposure-Response (E-R) Analysis to Support Benefit-Risk Assessment of Ipilimumab 3 vs 10 mg/kg in Patients with Advanced Melanoma
    Vezina, Heather E.
    Wang, Shelly
    Statkevich, Paul
    Bello, Akintunde
    Roy, Amit
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2018, 45 : S34 - S34
  • [7] CHARACTERIZATION OF EXPOSURE-RESPONSE (E-R) RELATIONSHIP FOR NIVOLUMAB IN SUBJECTS WITH ADVANCED MELANOMA PROGRESSING POST ANTI-CTLA4.
    Wang, X.
    Bajaj, G.
    Feng, Y.
    Gupta, M.
    Agrawal, S.
    Yang, A.
    Park, J.
    Roy, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S42 - S43
  • [8] Exposure-response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040)
    Sangro, Bruno
    Yau, Thomas
    El-Khoueiry, Anthony B.
    Kudo, Masatoshi
    Shen, Yun
    Tschaika, Marina
    Roy, Amit
    Feng, Yan
    Gao, Ling
    Aras, Urvi
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2023, 16 (08): : 1445 - 1457
  • [9] NIVOLUMAB EXPOSURE-RESPONSE (E-R) ANALYSIS FOR CLINICAL DEVELOPMENT OF NIVOLUMAB IN ADVANCED REFRACTORY SQUAMOUS NON-SMALL CELL LUNG CANCER.
    Feng, Y.
    Wang, X.
    Agrawal, S.
    Lestini, B.
    Park, J.
    Roy, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S7 - S7
  • [10] NIVOLUMAB EXPOSURE-RESPONSE (E-R) ANALYSIS FOR CLINICAL DEVELOPMENT OF NIVOLUMAB IN ADVANCED REFRACTORY SQUAMOUS NON-SMALL CELL LUNG CANCER.
    Feng, Y.
    Wang, X.
    Agrawal, S.
    Lestini, B.
    Park, J.
    Roy, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S57 - S58
12345